Markets:

Overview

News

Currencies

International

Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

3.085 +0.055 (+1.82%)

Delayed Quote Updated: 10:51 AM EST, Nov 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Ardelyx Targets $500M Revenue This Year, Profitability by 2027 ↗

September 21, 2026

Ardelyx (NASDAQ:ARDX) expects to generate close to $500 million in revenue this year and reach profitability in 2027, supported by continued growth of its IBS-C treatment IBSRELA and hyperphosphatemia...

Via MarketBeat

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Record revenue masks payer headwinds forcing IBSRELA guidance cuts.

Via The Motley Fool

Topics Earnings Economy

Ardelyx (NASDAQ:ARDX) Plunges After Q2 Miss and Guidance Cut ↗

August 06, 2026

Via Chartmill

Ardelyx Q2 Earnings Call Highlights ↗

August 06, 2026

Ardelyx (NASDAQ:ARDX) reported second-quarter product revenue of $118 million, up 31% from a year earlier and representing the company’s largest quarterly revenue total to date. The company lowered its...

Via MarketBeat

Topics Earnings

Ardelyx Inc (NASDAQ:ARDX) Reports Strong Q1 Revenue Beat as IBSRELA Momentum Accelerates ↗

April 30, 2026

Via Chartmill

Ardelyx Inc (NASDAQ:ARDX) Reports Q4 2025 Revenue Beat but EPS Miss, Shares Fall ↗

February 19, 2026

Via Chartmill

Ardelyx Stock Rises Premarket As Piper Sees Over 100% Upside — Says Constipation Drug ‘Stole The Show’ With 2026 Guidance ↗

January 09, 2026

Via Stocktwits

Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction ↗

June 23, 2026

This biotech specializing in gastrointestinal and cardiorenal therapies reported a notable insider sale following strong 1-year returns.

Via The Motley Fool

Topics Regulatory Compliance

Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach ↗

June 04, 2026

Ardelyx (NASDAQ:ARDX) executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to...

Via MarketBeat

Ardelyx (ARDX) Q1 2026 Earnings Transcript ↗

April 30, 2026

Ardelyx (ARDX) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Intellectual Property

Ardelyx Stock Slips After-Hours As $100M Shelf Filing Sparks Dilution Fears After Strong Q3 ↗

November 04, 2025

Via Stocktwits

Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela ↗

October 31, 2025

Via Stocktwits

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Ardelyx President and CEO Sells 41,000 Shares for $243,000 ↗

April 03, 2026

This biotech innovator in gastrointestinal and kidney therapies reported a notable insider sale amid routine portfolio adjustments.

Via The Motley Fool

Topics Regulatory Compliance

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership ↗

March 01, 2026

Ardelyx is coming off a strong Q4 earnings report for fiscal year 2025. But how is the stock performing?

Via The Motley Fool

Topics Regulatory Compliance

ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug ↗

February 24, 2026

On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels.

Via Stocktwits

Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗

February 23, 2026

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’.

Via Stocktwits

Topics Artificial Intelligence ETFs Government

ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? ↗

February 20, 2026

Analysts at H.C. Wainwright hiked their price target for Ardelyx shares to $18 from $10.

Via Stocktwits

Topics Earnings Intellectual Property

ARDX Stock Slips After Hours As Q4 Earnings Disappoint: Retail Sees Ibsrela Driving Outperformance In Time ↗

February 19, 2026

The company reported no earnings for the fourth quarter, compared to an analyst estimate of $0.01 per share.

Via Stocktwits

Topics Artificial Intelligence

Ardelyx Stock Is Rallying – What Is Making Retail So Bullish? ↗

January 08, 2026

The company said it made significant commercial progress in 2025, generating approximately $378 million in product revenue.

Via Stocktwits

Ardelyx (ARDX) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Ardelyx (ARDX) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Is Teladoc Stock a Buy After Oracle Investment Management Upped Its Stake? ↗

November 19, 2025

The investment company displayed confidence in Teladoc's growth potential by expanding its holdings in the stock.

Via The Motley Fool

Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 04, 2025

Via Benzinga

Why Upwork Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket ↗

November 04, 2025

Via Benzinga

Cloudflare Posts Upbeat Q3 Results, Joins Amazon, Roku, Coinbase, Atlassian And Other Big Stocks Moving Higher On Friday ↗

October 31, 2025

Via Benzinga

Discover the top movers in Friday's pre-market session. ↗

October 31, 2025

Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Why Amazon Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket ↗

October 31, 2025

Via Benzinga

Top movers in Thursday's after hours session ↗

October 30, 2025

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

Ardelyx Inc (NASDAQ:ARDX) Stock Surges on Q3 2025 Revenue Beat and Raised Guidance ↗

October 30, 2025

Ardelyx (ARDX) stock surged 15% after Q3 2025 results, beating revenue estimates with strong growth from its drug IBSRELA and raising its full-year guidance.

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 30, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.